The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/10 - 1/50.
ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody.
1/50 - 1/100. Predicted molecular weight: 70 kDa.
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Use a concentration of 5 µg/ml.
FunctionBeta-oxidation of fatty acids. The highest activity concerns the C6 to C10 chain length substrate. Converts the end product of pristanic acid beta oxidation, 4,8-dimethylnonanoyl-CoA, to its corresponding carnitine ester.
ICC/IF image of ab103448 stained T24/83 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum/ 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab103448 at 5 µg/mL overnight at +4°C. The secondary antibody (green) was DyLight® 488 Goat anti-Rabbit IgG (H+L) (ab96899) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Western blot - Anti-CROT antibody (ab103448)
All lanes : Anti-CROT antibody (ab103448) at 1/50 dilution
Lane 1 : K562 cell lysate Lane 2 : Mouse liver tissue lysate
ab103448, at a 1/50 dilution, staining CROT in formalin fixed and paraffin embedded Human brain tissue which was peroxidase conjugated to the secondary antibody, followed by DAB staining.
Flow Cytometry - Anti-CROT antibody (ab103448)
Flow cytometric analysis of K562 cells with ab103448 at a 1/10 dilution (bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.
References for Anti-CROT antibody (ab103448)
This product has been referenced in:
Horie T et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc1:e003376 (2012).
Read more (PubMed: 23316322) »
Rayner KJ et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature478:404-7 (2011).
Read more (PubMed: 22012398) »